Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 87 results for hepatitis c

  1. What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

    ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison? Any explanatory notes(if...

  2. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do...

  3. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do...

  4. What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

    Question What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the...

  5. How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

    for hepatitis B and C? Any explanatory notes(if applicable) None. Source guidance details Comes from guidance...

  6. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

  7. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    clinical data from people having treatment with the new generation of hepatitis C virus treatments. NICE agreed that such efforts should...

  8. Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?

    communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the...

  9. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available

  10. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  11. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

  12. Needle and syringe programmes (PH52)

    This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.

  13. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  14. Improving the uptake of Hepatitis B screening and vaccination in at-risk groups attending the sexual health service

    a NICE Scholarship project we aimed to improve awareness and uptake of Hepatitis B Screening and Vaccination in at-risk groups attending...

  15. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.